secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0000950170-22-009651
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics Q1 2022: Cash $246.8M; BDC-1001 data on track for H2 2022
------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $246.8M at March 31, 2022; expected to fund operations into 2024.
- Collaboration revenue $0.8M from Genmab and Innovent partnerships; R&D expenses $18.4M vs $14.1M prior year.
- Loss from operations $23.9M vs $18.4M in Q1 2021, reflecting increased clinical and IND-enabling activities.
- Lead ISAC BDC-1001 monotherapy and OPDIVO combo dose escalation on track; data readout expected H2 2022.
- IND-enabling activities for CEA-targeted BDC-2034 and Dectin-2 agonist BDC-3042 progressing; BDC-3042 clinical start planned 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000095017022009651/0000950170-22-009651-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000095017022009651/bolt-20220512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-009651

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer